Who are FTC/TDF + EFV or LPV/R +T20's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ftc-tdf-efv-or-lpv-r-t20.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

FTC/TDF + EFV or LPV/R +T20 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FTC/TDF + EFV or LPV/R +T20 (FTC/TDF + EFV or LPV/R +T20) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + NNRTI/PI + fusion inhibitor). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (NRTI + NNRTI/PI + fusion inhibitor) HIV reverse transcriptase, HIV protease, HIV gp41 fusion protein Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

FTC/TDF + EFV or LPV/R +T20 (FTC/TDF + EFV or LPV/R +T20) — French National Agency for Research on AIDS and Viral Hepatitis. This is a combination antiretroviral regimen that suppresses HIV replication through multiple mechanisms: nucleoside reverse transcriptase inhibition, non-nucleoside reverse transcriptase inhibition or protease inhibition, and fusion inhibition.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
FTC/TDF + EFV or LPV/R +T20 TARGET	FTC/TDF + EFV or LPV/R +T20	French National Agency for Research on AIDS and Viral Hepatitis	phase 3	Antiretroviral combination therapy (NRTI + NNRTI/PI + fusion inhibitor)	HIV reverse transcriptase, HIV protease, HIV gp41 fusion protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + NNRTI/PI + fusion inhibitor) class)

French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FTC/TDF + EFV or LPV/R +T20 — Competitive Intelligence Brief. https://druglandscape.com/ci/ftc-tdf-efv-or-lpv-r-t20. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab